Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons
Auteur James W. Keck
Auteur Lisa R. Bulkow
Auteur Gregory A. Raczniak
Auteur Susan E. Negus
Auteur Carolyn L. Zanis
Auteur Michael G. Bruce
Auteur Philip R. Spradling
Auteur Eyasu H. Teshale
Auteur Brian J. McMahon
Volume 21
Numéro 9
Pages 1339-1342
Publication Clinical and vaccine immunology: CVI
ISSN 1556-679X
Date Sep 2014
Résumé Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml.
Chercher cette référence sur : Google Scholar, Worldcat
doi:10.1128/CVI.00263-14
Laisser une réponse
Vous devez etre connectez Pour poster un commentaire